




RealRate

PHARMACEUTICAL 2020

Entasis Therapeutics Holdings Inc. Rank 162 of 358





RealRate

PHARMACEUTICAL 2020

Entasis Therapeutics Holdings Inc. Rank 162 of 358



The relative strengths and weaknesses of Entasis Therapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Entasis Therapeutics Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Entasis Therapeutics Holdings Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 77% points.

The company's Economic Capital Ratio, given in the ranking table, is 96%, being 59% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	49,006
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,556
Liabilities, Non-Current	1,321
Other Assets	1,683
Other Compr. Net Income	9.0
Other Expenses	677
Other Liabilities	0
Other Net Income	0
Other Revenues	10,763
Property and Equipment	345
Research and Development	40,166
Selling, General and Administrative Expense	13,770

Output Variable	Value in 1000 USD
Assets	51,034
Liabilities	8,877
Expenses	54,613
Revenues	10,763
Stockholders Equity	42,157
Net Income	-43,850
Comprehensive Net Income	-43,846
Economic Capital Ratio	96%